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The effect of Monensin on clinical mastitis in dairy cattle was evaluated from data collected at 
nine geographical clinical field trials using 966 Holstein cows and heifers in the United States 
and Canada.  At each site, a randomized complete block design was conducted.  Monensin 
(Rumensin®) was fed at concentrations of 0, 8, 16, or 24 ppm in a total mixed ration beginning 
21 days before first calving for all nine sites, up to 7 days after second calving for six sites, and 
203 days after second calving for three sites.  Quarter milk samples were taken and cultured to 
determine the causative pathogen for each mastitis case and if clinical signs were observed the 
disease data were grouped according to etiology and analyses conducted.  Analyses were 
conducted for all clinical mastitis cases as well as for a breakdown of the clinical mastitis cases 
into microorganism group levels.   
 
A generalized linear mixed model and a linear mixed model were used to determine if there were 
significant differences in clinical mastitis between the non-zero concentrations of Monensin and 
controls.  Response variables for the clinical mastitis cases that were analyzed using a 
generalized linear mixed model were Animal rate, Quarter rate, Observation rate, and Incident 
rate.  An additional response variable, Average case duration, was analyzed using a linear mixed 
model.  Inferences from the analyses indicate that Monensin does not influence the susceptibility 
of dairy cattle to clinical mastitis.  
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Mastitis is generally recognized as a very costly disease to the dairy industry.  It manifests itself 
in lowered milk yield, increased costs of production, and reduced milk quality. Annually, 
economic loss due to mastitis in the United States is estimated to be $185 per cow.  If the cost 
per cow is multiplied by the total number of milk cows (9.5 million head), the total annual loss of 
mastitis is about $1.8 billion. Therefore, it is critical to determine the impact of any new 
technology on mastitis. 
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Monensin has been fed to beef cattle in United States and twenty other countries for over twenty 
five years for the control of coccidiosis and the enhancement of growth performance.   
Studies were conducted to determine the effect of Monensin on milk production efficiency, 
health and safety in dairy cattle.  Nine clinical field trials were conducted in the United States 
and Canada which involved 966 Holstein cows and heifers.  Efficacy data as well as health and 
safety data were collected for each cow and pooled for analysis.  Clinical mastitis data were 




2.  MATERIALS AND METHODS 
 
Monensin was fed to dairy cattle at concentrations of 0, 8, 16, or 24 ppm in a total mixed ration 
(dry matter basis) at all nine sites, beginning approximately 21 days before anticipated calving 
(Calving 1) and continuing through the following lactation and dry period, until seven days after 
the next calving (Calving 2).  Feeding of Monensin continued in three of the nine sites until 
approximately 203 days in milk of the second lactation.  Of the 966 Holstein cows and heifers 
that started the study, only 372 were designated to continue in the three trial sites.  Of the 372 
animals, two hundred forty nine began the second lactation.   
 
 
3.  DATA COLLECTION AND SUMMARIZATION 
 
Cows were checked for clinical signs of mastitis at each milking.  Quarter milk samples were 
collected if clinical signs were observed.  Quarter milk samples collected were cultured to 
determine the causative pathogen if mastitis was detected, then the pathogen was classified 
according to etiology, Table 1, before being analyzed.  Individual incidents (cases) and the days 
over which incidents persisted were recorded for each quarter.  Data were then analyzed for each 
pathogen group, Table 1, as well as ignoring the pathogen classification, All Cases, Table 1, for 
each of five summary periods,  Table 2. 
 
 
4.  STATISTICAL METHODS  
 
Animal rate, Quarter rate, Incident rate, Observation rate, and Average case duration were 
analyzed at each group classification, Table 1, for each of five summary periods, Table 2.  
Counts and proportions (Animal, Quarter, Observation, and Incident rates) were treated as 
discrete variables, and Average case duration was treated as a continuous variable.    
 
For the count and proportion data, a generalized linear mixed model associated with each of the 
four response variables, Animal, Quarter, Observation and Incident rate, is given in Table 3.  The 
analyses were conducted using the GLIMMIX macro, SAS V6.12.  If the criterion for using a 
generalized linear mixed model was not met or if the model failed to converge, then an exact 
method, Proc StatXact® v4.0 (Mehta and Patel, 1987), was conducted.  If the data were too 
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sparse, for instance, when both parity groups had less than three observations, then a frequency 
table was created. 
 
 For the continuous response variable, Average case duration, a linear mixed model was used 
(Table 4).  The analysis was conducted using Proc Mixed SAS V6.12. 
 
 
5.  RESULTS 
 
Results will focus on two periods of the study, Calving 30-CD and 50-CE, Table 2, at All Cases 
level since 94.1% of the clinical mastitis incidents occurred during these two periods.  Tables 5 
and 6  show the etiology of mastitis cases by Monensin concentrations for each of the five 
variables Animal rate, Quarter rate, Observation rate, Incident rate and Average case duration 
during 30-CD and 50-CE, respectively.  
 
For the 30-CD period, no Parity by Treatment interactions were detected (P > 0.25) and no 
Monensin effects were detected (P > 0.10) for Animal, Quarter, Observation, or Incident rates, as 
well as Average case duration (Table 5). 
 
For the 50–CE period, Parity by Treatment interaction was detected (P = 0.01) for Average case 
duration. Therefore, analyses for Average case duration were conducted for each parity.  
Observation rate for clinical mastitis was lower (P < 0.10) in the 24 ppm Monensin group than 
the controls (Table 6).  However, there is no indication that Monensin should reduce Observation 
rate in dairy cattle.  No other effects were detected (P > 0.10) for either Animal, Quarter or 
Incident rate.  For Average case duration, primiparous cattle receiving Monensin at 8 ppm had a 
longer duration than controls (P = 0.01, Table 6).  This was caused by one cow from the 8 ppm 
group with a case duration 320 days.   
 
 
6.  SUMMARY  
 
Monensin did not adversely affect the incidence or duration of clinical mastitis across etiologies, 
in either the first or second lactation of dairy cattle. 
 
When clinical mastitis data were analyzed at All Cases level, some significant differences 
between non-zero concentration of Monensin and control were detected.  No significant 
differences were detected for any rate or duration variable for the period 30-CD. A significant 
Observation rate reduction for the 24 ppm Monensin group, and a significant longer Average 
case duration for the 8 ppm Monensin group were detected when compared to control for the 
period, 50-CE.  In general, no consistent patterns indicating that Monensin adversely affect the 
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7.  CONCLUSION 
 
We found no evidence to indicate that Monensin influences the susceptibility of dairy cattle to 
clinical mastitis.  
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All Cases ALL All clinical mastitis cases regardless of culture results 
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Table 2.  List of Five Summary Periods for Clinical Mastitis Cases 
 
Period Description 
05-TC Treatment start to Calving 1 
30-CD Calving 1 to Dry-Off 
35-DC Dry-off to Calving 2 
45-C7 Calving 2 to 7 DIM 
50-CE Calving 2 to 203 DIM 
                             DIM: Days in milk
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Table 3. Generalized Linear Mixed Model for Animal, Quarter, Observation, and Incident Rate 
 
ghihjhgjjgghij PP)(g γβ+γτ+γ+τ+τ++µ=η , where 
)and,,|X(E ghihjhghijghij γβγτγ=η  for Animal rate, 
)and,,|Q/Y(E ghihjhghijghijghij γβγτγ=η for Quarter rate, 
)R(logbyoffset)and,,|O(E ghijeghihjhghijghij γβγτγ=η for Observation rate, 
)and,,|R/C(E ghihjhghijghijghij γβγτγ=η for Incident rate, 
 g(•) = link function (logit or loge) used to linearize conditional mean for GLIMM. 
 and 
µ Common mean γh Trial site effect 
g Indicates parity 
Pg Parity effect 
γτhj Trial by treatment 
interaction 
h 
Indicates the hth trial site 
τ j Treatment effect 
γβghi Block within trial site 
effect 
i 
Indicates the ith block 
Pτgj Parity by treatment 
interaction 




Table 4.  Linear Mixed Model for Average Case Duration 
 
ε+νΖ+β= XY , where 
gjjg PPX τ+τ++µ=β , and 
ghihjhZ γβ+γτ+γ=ν . 
Where 
µ Common mean γh Trial site effect 
g Indicates parity 
Pg Parity effect 
γτhj Trial by treatment 
interaction 
h 
Indicates the hth trial site 
τ j Treatment effect 
γβghi Block within trial site 
effect 
i 
Indicates the ith block 
Pτgj Parity by treatment 
interaction 
  j Indicates the jth treatment 
group 
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Table 5.  Summary of Clinical Mastitis Incidents (All Cases) in the Calving 1 to Dry-Off Period 
Across All Sites. 
 
 Monensin Concentration (ppm) 
Variables 0 8 16 24 
Animal rate 0.472 0.451 0.405 0.428 
Quarter rate 0.200 0.197    0.175 0.185 
Observation rate (per 1000 quarter 
days at risk) 
  4.375 5.164 4.665 5.011 
Incident rate (per 1000 quarter 
days at risk) 
0.893 0.865 0.749 0.764 
Average case duration (days ) 7.34 8.82 7.48 8.12 
                        Note:  Monensin non –zero concentration means were not different from controls. 
 
 
Table 6.  Summary of Clinical Mastitis Incidents (All Cases) in the Calving 2 to 203 DIM Period 
Across All Sites  
 
 Monensin Concentration (ppm) 
Variables 0 8 16 24 
Animal rate 0.589 0.521 0.490 0.478 
Quarter rate 0.279 0.239 0.213 0.200 
Observation rate (per 1000 days at 
risk) 
13.570 15.713 13.317 7.804* 
Incident rate (per 1000 days at risk) 1.90 1.716 1.907 1.511 
Average case duration, days - 
Multiparous 
14.12 8.5 10.06 10.93 
Average case duration, days - 
Primiparous 
16.78 34.54* 14.36 9.95 
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